Guidelines for prescribing combined oral contraceptivesBMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7023.121a (Published 13 January 1996) Cite this as: BMJ 1996;312:121
- A M Mills,
- C L Wilkinson,
- D R Bromham,
- J Elias,
- K Fotherby,
- J Guillebaud,
- A Kubba,
- A Wade
- (chair, clinical and scientific committee), (secretary), (committee member), (committee member), (committee member), (committee member), (committee member), (committee member) Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists, London NW1 4RG
EDITOR,—The clinical and scientific committee of the Faculty of Family Planning and Reproductive Health Care has noted a wide range of expert views on the recent publications on the combined oral contraceptive and venous thromboembolism1 2 3 4 5 6 and has circulated a position paper.7 The new studies confirm that low dose combined oral contraceptives carry an extremely low risk for healthy women.
The overall risk of venous thromboembolism for users of combined oral contraceptives containing gestodene and desogestrel is close to the previous estimate for all low dose combined oral contraceptives.5 Combined oral contraceptives containing levonorgestrel and norethisterone seem to be associated with a lower risk of non-fatal venous thromboembolism than previously reported (table).
Prescribers should take a comprehensive personal and family history to exclude absolute contraindications to the use of combined oral contraceptives. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial